详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Icariin alleviates oxygen-induced retinopathy by targeting microglia hexokinase 2

11| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China. [2]Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China. [3]Beijing Tongren Eye Center, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Capital Medical University, Beijing, China.

出处：

DOI：

ISSN：

关键词： angiogenesis hexokinase 2 icariin microglia oxygen-induced retinopathy

摘要：

Retinopathy of prematurity (ROP) is a retinal disease-causing retinal neovascularization that can lead to blindness. Oxygen-induced retinopathy (OIR) is a widely used ROP animal model. Icariin (ICA) has anti-oxidative and anti-inflammation properties; however, whether ICA has a regulatory effect on OIR remains unclear. In this study, ICA alleviated pathological neovascularization, microglial activation and blood-retina barrier (BRB) damage in vivo. Further results indicated that endothelial cell tube formation, migration and proliferation were restored by ICA treatment in vitro. Proteomic microarrays and molecular mimicry revealed that ICA can directly bind to hexokinase 2 (HK2) and decrease HK2 protein expression in vivo and in vitro. In addition, ICA inhibited the AKT/mTOR/HIF1α pathway activation. The effects of ICA on pathological neovascularization, microglial activation and BRB damage disappeared after HK2 overexpression in vivo. Similarly, the endothelial cell function was revised after HK2 overexpression. HK2 overexpression reversed ICA-induced AKT/mTOR/HIF1α pathway inhibition in vivo and in vitro. Therefore, ICA prevented pathological angiogenesis in OIR in an HK2-dependent manner, implicating ICA as a potential therapeutic agent for ROP.© 2024 John Wiley & Sons Ltd.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区免疫学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区免疫学

JCR分区：

出版当年[2022]版：

Q2 IMMUNOLOGY

最新[2023]版：

Q2 IMMUNOLOGY

影响因子： 4.9 最新[2023版] 6.6 最新五年平均 6.4 出版当年[2022版] 7 出版当年五年平均 7.215 出版前一年[2021版] 4.9 出版后一年[2023版]

第一作者：

第一作者机构： [1]The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy [2]Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy [3]Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies [4]可定量的氧致血管增生性视网膜病变小鼠模型 [5]Cedilanid inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy [6]Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy [7]YY1 lactylation in microglia promotes angiogenesis through transcription activation-mediated upregulation of FGF2 [8]毛花甙丙抑制氧诱导乳鼠视网膜新生血管的实验研究 [9]氧诱导视网膜病变动物模型在视网膜新生血管治疗中的应用 [10]Autophagy-mediated activation of the AIM2 inflammasome enhances M1 polarization of microglia and exacerbates retinal neovascularization